{
    "abstract": " Trastuzumab is a humanized monoclonal antibody against HER2 approved by FDA for breast and gastric cancer therapy. However, only a quarter of patients have the potential to benefit from it, and most of them develop resistance within therapy. The main purpose of this study is to broaden trastuzumab's therapeutic window by conjugating trastuzumab with recombinant cucurmosin to form an immunotoxin called T-CUS 245C . T-CUS 245C was chemically conjugated and the purification of T-CUS 245C was evaluated by SDS-PAGE. SRB tests showed a remarkable cytotoxicity of T-CUS 245C with IC 50 values in picomolar range on HER2 positive cancer cells without significantly proliferation inhibition on HER2 negative cells (P < 0.01). Confocal microscopy verified the time-dependent internalization effects of T-CUS 245C and revealed that the lethal efficacy can be increased by provoking the internalization. These results indicate the therapeutic potential of T-CUS 245C for the HER-2 targeted therapy. ",
    "author_highlights": [
        {
            "endOffset": 12751,
            "sentence": "Construction and purification of a chemically conjugated immunotoxin T-CUS245C.",
            "startOffset": 12672
        },
        {
            "endOffset": 12873,
            "sentence": "Verification of the anti-tumor cytotoxicity and antigen specificity of T-CUS245C in vitro.",
            "startOffset": 12783
        },
        {
            "endOffset": 12961,
            "sentence": "The internalization effects of T-CUS245C and its role playing in cell killing efficacy.",
            "startOffset": 12874
        }
    ],
    "bib_entries": {
        "bib1": {
            "authors": [
                {
                    "first": "Jayaprakasam",
                    "initial": "J.",
                    "last": "Madhumathi"
                },
                {
                    "first": "Sithambaram",
                    "initial": "S.",
                    "last": "Devilakshmi"
                },
                {
                    "first": "Surapally",
                    "initial": "S.",
                    "last": "Sridevi"
                },
                {
                    "first": "Rama S.",
                    "initial": "R.S.",
                    "last": "Verma"
                }
            ],
            "doi": "10.1016/j.drudis.2015.05.002",
            "firstpage": "325",
            "issn": "13596446",
            "lastpage": "332",
            "pmid": "26049016",
            "pub_year": 2016,
            "title": "Immunotoxin therapy for hematologic malignancies: Where are we heading?",
            "volume": "21"
        },
        "bib10": {
            "authors": [
                {
                    "first": "Dennis J.",
                    "initial": "D.J.",
                    "last": "Slamon"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Leyland-Jones"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Shak"
                },
                {
                    "first": "Hank",
                    "initial": "H.",
                    "last": "Fuchs"
                },
                {
                    "first": "Virginia",
                    "initial": "V.",
                    "last": "Paton"
                },
                {
                    "first": "Alex",
                    "initial": "A.",
                    "last": "Bajamonde"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Fleming"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Eiermann"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Wolter"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Pegram"
                },
                {
                    "first": "Jose",
                    "initial": "J.",
                    "last": "Baselga"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Norton"
                }
            ],
            "doi": "10.1056/NEJM200103153441101",
            "firstpage": "783",
            "issn": "00284793",
            "lastpage": "792",
            "pmid": "11248153",
            "pub_year": 2001,
            "title": "Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2",
            "volume": "344"
        },
        "bib11": {
            "authors": [
                {
                    "first": "Vicente",
                    "initial": "V.",
                    "last": "Valero"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Forbes"
                },
                {
                    "first": "Mark D.",
                    "initial": "M.D.",
                    "last": "Pegram"
                },
                {
                    "first": "Tadeusz",
                    "initial": "T.",
                    "last": "Pienkowski"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Eiermann"
                },
                {
                    "first": "Gunter",
                    "initial": "G.",
                    "last": "Von Minckwitz"
                },
                {
                    "first": "Henri",
                    "initial": "H.",
                    "last": "Roche"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "Martin"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Crown"
                },
                {
                    "first": "John R.",
                    "initial": "J.R.",
                    "last": "Mackey"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Fumoleau"
                },
                {
                    "first": "Janusz",
                    "initial": "J.",
                    "last": "Rolski"
                },
                {
                    "first": "Zrinka",
                    "initial": "Z.",
                    "last": "Mrsic-Krmpotic"
                },
                {
                    "first": "Agnieszka",
                    "initial": "A.",
                    "last": "Jagiello-Gruszfeld"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Riva"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Buyse"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Taupin"
                },
                {
                    "first": "Guido",
                    "initial": "G.",
                    "last": "Sauter"
                },
                {
                    "first": "Michael F.",
                    "initial": "M.F.",
                    "last": "Press"
                },
                {
                    "first": "Dennis J.",
                    "initial": "D.J.",
                    "last": "Slamon"
                }
            ],
            "doi": "10.1200/JCO.2010.28.6450",
            "firstpage": "149",
            "issn": "0732183X",
            "lastpage": "156",
            "pub_year": 2011,
            "title": "Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 Study): Two highly active therapeutic regimens",
            "volume": "29"
        },
        "bib12": {
            "authors": [
                {
                    "first": "Willy J.",
                    "initial": "W.J.",
                    "last": "Peumans"
                },
                {
                    "first": "Qiang",
                    "initial": "Q.",
                    "last": "Hao"
                },
                {
                    "first": "Els J.M.",
                    "initial": "E.J.M.",
                    "last": "Van Damme"
                }
            ],
            "doi": "10.1096/fj.00-0751rev",
            "firstpage": "1493",
            "issn": "08926638",
            "lastpage": "1506",
            "pmid": "11427481",
            "pub_year": 2001,
            "title": "Ribosome-inactivating proteins from plants: More than RNA N-glycosidases?",
            "volume": "15"
        },
        "bib13": {
            "authors": [
                {
                    "first": "Chun Sen",
                    "initial": "C.S.",
                    "last": "Xu"
                },
                {
                    "first": "He Guang",
                    "initial": "H.G.",
                    "last": "Huang"
                },
                {
                    "first": "Ming Huang",
                    "initial": "M.H.",
                    "last": "Chen"
                }
            ],
            "firstpage": "234",
            "issn": "10035370",
            "lastpage": "238",
            "pmid": "22574600",
            "pub_year": 2012,
            "title": "[Effects of cucurmosin on the cell proliferation and apoptosis in human pancreatic PANC-1 cells].",
            "volume": "32"
        },
        "bib14": {
            "authors": [
                {
                    "first": "Jieming",
                    "initial": "J.",
                    "last": "Xie"
                },
                {
                    "first": "Congfei",
                    "initial": "C.",
                    "last": "Wang"
                },
                {
                    "first": "Baoming",
                    "initial": "B.",
                    "last": "Zhang"
                },
                {
                    "first": "Aiqin",
                    "initial": "A.",
                    "last": "Yang"
                },
                {
                    "first": "Qiang",
                    "initial": "Q.",
                    "last": "Yin"
                },
                {
                    "first": "Heguang",
                    "initial": "H.",
                    "last": "Huang"
                },
                {
                    "first": "Minghuang",
                    "initial": "M.",
                    "last": "Chen"
                }
            ],
            "doi": "10.1016/S1734-1140(13)71046-6",
            "firstpage": "682",
            "issn": "17341140",
            "lastpage": "688",
            "pmid": "23950591",
            "pub_year": 2013,
            "title": "Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-\u03b2 signalling pathway",
            "volume": "65"
        },
        "bib15": {
            "authors": [
                {
                    "first": "Jieming",
                    "initial": "J.",
                    "last": "Xie"
                },
                {
                    "first": "Congfei",
                    "initial": "C.",
                    "last": "Wang"
                },
                {
                    "first": "Aiqin",
                    "initial": "A.",
                    "last": "Yang"
                },
                {
                    "first": "Baoming",
                    "initial": "B.",
                    "last": "Zhang"
                },
                {
                    "first": "Qiang",
                    "initial": "Q.",
                    "last": "Yin"
                },
                {
                    "first": "Heguang",
                    "initial": "H.",
                    "last": "Huang"
                },
                {
                    "first": "Minghuang",
                    "initial": "M.",
                    "last": "Chen"
                }
            ],
            "doi": "10.2174/18715206113139990109",
            "firstpage": "952",
            "issn": "18715206",
            "lastpage": "956",
            "pmid": "23157594",
            "pub_year": 2013,
            "title": "Cucurmosin kills human pancreatic cancer SW-1990 cells in vitro and in vivo",
            "volume": "13"
        },
        "bib16": {
            "authors": [
                {
                    "first": "Minghuang",
                    "initial": "M.",
                    "last": "Chen"
                },
                {
                    "first": "Xiaoming",
                    "initial": "X.",
                    "last": "Ye"
                },
                {
                    "first": "Jianhua",
                    "initial": "J.",
                    "last": "Cai"
                },
                {
                    "first": "Yujuan",
                    "initial": "Y.",
                    "last": "Lin"
                }
            ],
            "doi": "10.1107/S0907444900003322",
            "firstpage": "665",
            "issn": "09074449",
            "lastpage": "666",
            "pmid": "10771444",
            "pub_year": 2000,
            "title": "Crystallization and preliminary crystallographic study of cucurmosin, a ribosome-inactivating protein from the sarcocarp of Cucurbita moschata",
            "volume": "56"
        },
        "bib17": {
            "authors": [
                {
                    "first": "Congfei",
                    "initial": "C.",
                    "last": "Wang"
                },
                {
                    "first": "Aiqin",
                    "initial": "A.",
                    "last": "Yang"
                },
                {
                    "first": "Baoming",
                    "initial": "B.",
                    "last": "Zhang"
                },
                {
                    "first": "Qiang",
                    "initial": "Q.",
                    "last": "Yin"
                },
                {
                    "first": "Heguang",
                    "initial": "H.",
                    "last": "Huang"
                },
                {
                    "first": "Minghuang",
                    "initial": "M.",
                    "last": "Chen"
                },
                {
                    "first": "Jieming",
                    "initial": "J.",
                    "last": "Xie"
                }
            ],
            "doi": "10.1097/MPA.0000000000000087",
            "firstpage": "291",
            "issn": "08853177",
            "lastpage": "297",
            "pmid": "24518510",
            "pub_year": 2014,
            "title": "PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug",
            "volume": "43"
        },
        "bib18": {
            "authors": [
                {
                    "first": "Dan Ning",
                    "initial": "D.N.",
                    "last": "Hu"
                }
            ],
            "doi": "10.1111/j.1751-1097.2007.00228.x",
            "firstpage": "645",
            "issn": "00318655",
            "lastpage": "649",
            "pmid": "18435617",
            "pub_year": 2008,
            "title": "Methodology for evaluation of melanin content and production of pigment cells in vitro",
            "volume": "84"
        },
        "bib19": {
            "authors": [
                {
                    "first": "Cuimin",
                    "initial": "C.",
                    "last": "Deng"
                },
                {
                    "first": "Jiani",
                    "initial": "J.",
                    "last": "Xiong"
                },
                {
                    "first": "Xiaofan",
                    "initial": "X.",
                    "last": "Gu"
                },
                {
                    "first": "Xiaoying",
                    "initial": "X.",
                    "last": "Chen"
                },
                {
                    "first": "Shuifa",
                    "initial": "S.",
                    "last": "Wu"
                },
                {
                    "first": "Zhe",
                    "initial": "Z.",
                    "last": "Wang"
                },
                {
                    "first": "Duanduan",
                    "initial": "D.",
                    "last": "Wang"
                },
                {
                    "first": "Jinjin",
                    "initial": "J.",
                    "last": "Tu"
                },
                {
                    "first": "Jieming",
                    "initial": "J.",
                    "last": "Xie"
                }
            ],
            "doi": "10.18632/oncotarget.16930",
            "firstpage": "38568",
            "issn": "19492553",
            "lastpage": "38580",
            "pub_year": 2017,
            "title": "Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro",
            "volume": "8"
        },
        "bib2": {
            "authors": [
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Donaghy"
                }
            ],
            "doi": "10.1080/19420862.2016.1156829",
            "firstpage": "659",
            "issn": "19420862",
            "lastpage": "671",
            "pmid": "27045800",
            "pub_year": 2016,
            "title": "Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates",
            "volume": "8"
        },
        "bib20": {
            "authors": [
                {
                    "first": "Roger R.",
                    "initial": "R.R.",
                    "last": "Beerli"
                },
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Hell"
                },
                {
                    "first": "Anna S.",
                    "initial": "A.S.",
                    "last": "Merkel"
                },
                {
                    "first": "Ulf",
                    "initial": "U.",
                    "last": "Grawunder"
                }
            ],
            "doi": "10.1371/journal.pone.0131177",
            "issn": "19326203",
            "pmid": "26132162",
            "pub_year": 2015,
            "title": "Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high In Vitro and In Vivo potency",
            "volume": "10"
        },
        "bib3": {
            "authors": [
                {
                    "first": "Arthur E.",
                    "initial": "A.E.",
                    "last": "Frankel"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Kreitman"
                },
                {
                    "first": "Edward A.",
                    "initial": "E.A.",
                    "last": "Sausville"
                }
            ],
            "firstpage": "326",
            "issn": "10780432",
            "lastpage": "334",
            "pmid": "10690507",
            "pub_year": 2000,
            "title": "Targeted toxins",
            "volume": "6"
        },
        "bib4": {
            "authors": [
                {
                    "first": "Christopher M.",
                    "initial": "C.M.",
                    "last": "Pirie"
                },
                {
                    "first": "Benjamin J.",
                    "initial": "B.J.",
                    "last": "Hackel"
                },
                {
                    "first": "Michael G.",
                    "initial": "M.G.",
                    "last": "Rosenblum"
                },
                {
                    "first": "K. Dane",
                    "initial": "K.D.",
                    "last": "Wittrup"
                }
            ],
            "doi": "10.1074/jbc.M110.186973",
            "firstpage": "4165",
            "issn": "00219258",
            "lastpage": "4172",
            "pmid": "21138845",
            "pub_year": 2011,
            "title": "Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties",
            "volume": "286"
        },
        "bib5": {
            "authors": [
                {
                    "first": "Ronit",
                    "initial": "R.",
                    "last": "Mazor"
                },
                {
                    "first": "Emily M.",
                    "initial": "E.M.",
                    "last": "King"
                },
                {
                    "first": "Ira",
                    "initial": "I.",
                    "last": "Pastan"
                }
            ],
            "doi": "10.1016/j.ajpath.2018.04.016",
            "firstpage": "1736",
            "issn": "00029440",
            "lastpage": "1743",
            "pmid": "29870741",
            "pub_year": 2018,
            "title": "Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins",
            "volume": "188"
        },
        "bib6": {
            "authors": [
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Kreitman"
                },
                {
                    "first": "Maryalice",
                    "initial": "M.",
                    "last": "Stetler-Stevenson"
                },
                {
                    "first": "Inger",
                    "initial": "I.",
                    "last": "Margulies"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Noel"
                },
                {
                    "first": "David J.P.",
                    "initial": "D.J.P.",
                    "last": "FitzGerald"
                },
                {
                    "first": "Wyndham H.",
                    "initial": "W.H.",
                    "last": "Wilson"
                },
                {
                    "first": "Ira",
                    "initial": "I.",
                    "last": "Pastan"
                }
            ],
            "doi": "10.1200/JCO.2008.20.2630",
            "firstpage": "2983",
            "issn": "0732183X",
            "lastpage": "2990",
            "pmid": "19414673",
            "pub_year": 2009,
            "title": "Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia",
            "volume": "27"
        },
        "bib7": {
            "authors": [
                {
                    "first": "Frank R.",
                    "initial": "F.R.",
                    "last": "Brennan"
                },
                {
                    "first": "Laura Dill",
                    "initial": "L.D.",
                    "last": "Morton"
                },
                {
                    "first": "Sebastian",
                    "initial": "S.",
                    "last": "Spindeldreher"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Kiessling"
                },
                {
                    "first": "Roy",
                    "initial": "R.",
                    "last": "Allenspach"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Hey"
                },
                {
                    "first": "Patrick Y.",
                    "initial": "P.Y.",
                    "last": "Muller"
                },
                {
                    "first": "Werner",
                    "initial": "W.",
                    "last": "Frings"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Sims"
                }
            ],
            "doi": "10.4161/mabs.2.3.11782",
            "firstpage": "233",
            "issn": "19420862",
            "lastpage": "255",
            "pmid": "20421713",
            "pub_year": 2010,
            "title": "Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies",
            "volume": "2"
        },
        "bib8": {
            "authors": [
                {
                    "first": "Diana P.",
                    "initial": "D.P.",
                    "last": "English"
                },
                {
                    "first": "Dana M.",
                    "initial": "D.M.",
                    "last": "Roque"
                },
                {
                    "first": "Alessandro D.",
                    "initial": "A.D.",
                    "last": "Santin"
                }
            ],
            "doi": "10.1007/s40291-013-0024-9",
            "firstpage": "85",
            "issn": "11771062",
            "lastpage": "99",
            "pmid": "23529353",
            "pub_year": 2013,
            "title": "HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies",
            "volume": "17"
        },
        "bib9": {
            "authors": [
                {
                    "first": "Y. F.",
                    "initial": "Y.F.",
                    "last": "Yu"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "T. P.",
                    "initial": "T.P.",
                    "last": "Fu"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Chen"
                },
                {
                    "first": "J. Q.",
                    "initial": "J.Q.",
                    "last": "Liu"
                },
                {
                    "first": "H. R.",
                    "initial": "H.R.",
                    "last": "Yao"
                }
            ],
            "doi": "10.1007/s10549-017-4592-y",
            "firstpage": "337",
            "issn": "01676806",
            "lastpage": "348",
            "pmid": "29188398",
            "pub_year": 2018,
            "title": "Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer",
            "volume": "168"
        }
    },
    "body_text": [
        {
            "endOffset": 18262,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "The lysate was centrifuged twice for 20 min at 4 \u00b0C and purified by Ni-NTA.",
            "startOffset": 18187,
            "title": "CUS245C expression"
        },
        {
            "endOffset": 30238,
            "parents": [],
            "secId": "sec4",
            "sentence": "In addition, no antigen binding affinity changed by extra CUS245C conjugation (Fig. 1C).",
            "startOffset": 30150,
            "title": "Discussion"
        },
        {
            "endOffset": 17223,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                },
                {
                    "id": "sec2.1",
                    "title": "Cell lines and reagents"
                }
            ],
            "secId": "sec2.1.1",
            "sentence": "Human breast cancer cell lines MDA-MB-231, MCF-7, SK-BR-3, BT-474, and human ovarian carcinoma cell lines SKOV-3 were obtained from ATCC.",
            "startOffset": 17086,
            "title": "Cell line"
        },
        {
            "endOffset": 22384,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "As shown in 6% SDS-PAGE (Fig. A), the conjugations were the mixtures of T-CUS245C, T-PDP, CUS245C, and CUS245C dimers (Fig. A1 Lane 1).",
            "startOffset": 22249,
            "title": "T-CUS245C construction"
        },
        {
            "endOffset": 20521,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "The dosage/time-effect curve was drawn using GraphPad Prism 5 (GraphPad Software).",
            "startOffset": 20439,
            "title": "Cytotoxic activity"
        },
        {
            "endOffset": 22617,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "Purified T-CUS245C was finally obtained (Fig. A4 Lane 1,4, and 5).",
            "startOffset": 22551,
            "title": "T-CUS245C construction"
        },
        {
            "endOffset": 20438,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Colorimetry was performed at 515 nm with Epoch Microplate Reader (BioTek instrument, Inc).",
            "startOffset": 20348,
            "title": "Cytotoxic activity"
        },
        {
            "endOffset": 24430,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Although the cellular proliferation inhibition on day 3 is slightly mild for the T-CUS245C treatment compared with the 5-day ones, its IC50 on SK-OV-3 is 10 times lower than T-DM1, an FDA approved trastuzumab-depend antibody drug conjugates (ADCs), with similar IC50 on other HER2 positive cells (Table 1).",
            "startOffset": 24124,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 15589,
            "parents": [],
            "refoffsets": {
                "bib13": {
                    "endOffset": 15587,
                    "startOffset": 15582
                },
                "bib14": {
                    "endOffset": 15587,
                    "startOffset": 15582
                },
                "bib15": {
                    "endOffset": 15587,
                    "startOffset": 15582
                }
            },
            "secId": "sec1",
            "sentence": "It was isolated by our group from Cucurbita moschata (pumpkin) which function through inhibition of protein synthesis based on a unique catalytic mechanism [13\u201315].",
            "startOffset": 15425,
            "title": "Introduction"
        },
        {
            "endOffset": 21065,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.7",
            "sentence": "To analyze the pathway of T-CUS245C internalization cells were incubated with 1 ng/ml T-CUS245C for 1 h, 4 h and 10 h respectively at 37 \u00b0C.",
            "startOffset": 20925,
            "title": "Confocal microscopy"
        },
        {
            "endOffset": 16505,
            "parents": [],
            "secId": "sec1",
            "sentence": "Then we characterized its biological activity applying SDS-PAGE, Western blotting and flow cytometry, and assessing their cytotoxicity against variety of cancer cell lines, and then investigated the correlation of biological characteristics in terms of internalization utilizing confocal microscopy.",
            "startOffset": 16206,
            "title": "Introduction"
        },
        {
            "endOffset": 22908,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "Flow cytometry analysis showed an overlay of fluorescent value range of T-CUS245C and trastuzumab, indicated that the binding capacity of T-CUS245C was not impaired by CUS245C conjugation (Fig. 1C).",
            "startOffset": 22710,
            "title": "T-CUS245C construction"
        },
        {
            "endOffset": 20347,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Briefly, cells in logarithmic phase were seeded in 96-well plates with 3 \u00d7 104/ml per well and allowed to attach overnight before they were treated with CUS245C, Trastuzumab, and T-CUS245C for 3d and 5d, respectively.",
            "startOffset": 20130,
            "title": "Cytotoxic activity"
        },
        {
            "endOffset": 25071,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "(Fig. 2).",
            "startOffset": 25062,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 18186,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "IPTG (1 mM) were used for expression induction at 25 \u00b0C for 16\u201318 h. Cells were later sonicated (Sonics 5s, pulse10s, Ampl 60%) in PBS containing 0.068 mM Lysozyme for 60min.",
            "startOffset": 18012,
            "title": "CUS245C expression"
        },
        {
            "endOffset": 17420,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                },
                {
                    "id": "sec2.1",
                    "title": "Cell lines and reagents"
                }
            ],
            "secId": "sec2.1.2",
            "sentence": "pET-32a vector (+) and E.coli BL21 (DE3), his-tagged fusion protein kit (Sangon Biotech, Shanghai).",
            "startOffset": 17321,
            "title": "Reagents"
        },
        {
            "endOffset": 22492,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "The residual of CUS245C and T-PDP were removed by dialysis and Ni-NTA column successfully (Fig. A1 Lane 2).",
            "startOffset": 22385,
            "title": "T-CUS245C construction"
        },
        {
            "endOffset": 20615,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "Each experiment was repeated triple times.",
            "startOffset": 20573,
            "title": "Cytotoxic activity"
        },
        {
            "endOffset": 31008,
            "parents": [],
            "refoffsets": {
                "bib20": {
                    "endOffset": 30848,
                    "startOffset": 30846
                }
            },
            "secId": "sec4",
            "sentence": "Temptingly, in comparison with other trastuzumab-based conjugates, such as trastuzumab-DM1, trastuzumab-maytansine, and anti-HER2-curcin, which IC50 values for SK-BR-3 is around 48.4 ng/ml (\u2248323pM), 40.5 ng/ml (\u2248270pM), and 4 nM, respectively [20], the antitumor efficacy of T-CUS245C is extremely remarkable with IC50 ten times, even thousand times lower than trastuzumab-based conjugates mentioned above.",
            "startOffset": 30602,
            "title": "Discussion"
        },
        {
            "endOffset": 19996,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "Each experiment was repeated triple times.",
            "startOffset": 19954,
            "title": "Flow cytometry"
        },
        {
            "endOffset": 14472,
            "parents": [],
            "secId": "sec1",
            "sentence": "Understand how they function as cell killing agents and how to promote their anti-tumor efficacy is of great priority.",
            "startOffset": 14354,
            "title": "Introduction"
        },
        {
            "endOffset": 30149,
            "parents": [],
            "secId": "sec4",
            "sentence": "In this study, we proposed an alternative chemical conjugation strategy to obtain T-CUS245C with a decent yield around 50% and almost 100% purity (Fig. A).",
            "startOffset": 29994,
            "title": "Discussion"
        },
        {
            "endOffset": 14353,
            "parents": [],
            "secId": "sec1",
            "sentence": "Therefore, to achieve a higher anti-tumor response, a potent toxic payload and an intact antibody against tumor associated antigen (TAA) are not enough.",
            "startOffset": 14201,
            "title": "Introduction"
        },
        {
            "endOffset": 21441,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.7",
            "sentence": "Images were obtained by confocal microscopy using LSM 710 system (Carl Zeiss) with 63 \u00d7 water C-Apochromat objective.",
            "startOffset": 21324,
            "title": "Confocal microscopy"
        },
        {
            "endOffset": 23250,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "SRB analysis were applied to determine living cells and OD515 values were later measured.",
            "startOffset": 23161,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 32372,
            "parents": [],
            "secId": "sec5",
            "sentence": "The authors declare no conflict of interest.",
            "startOffset": 32328,
            "title": "Conflicts of interest"
        },
        {
            "endOffset": 16640,
            "parents": [],
            "secId": "sec1",
            "sentence": "The promising results showed an almost fully retained antitumor efficacy in the picomolar range against antigen positive cancer cells.",
            "startOffset": 16506,
            "title": "Introduction"
        },
        {
            "endOffset": 18011,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "Bacterial cells transferred with the pET32a (+)-CUS245C were cultivated at 37 \u00b0C in LB medium at 200 rpm on a rotary shaker until OD600 reached 0.8.",
            "startOffset": 17863,
            "title": "CUS245C expression"
        },
        {
            "endOffset": 19634,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "Cell surface HER2 expressions of MDA-MB-231, MCF-7, SK-BR-3, BT-474, and SK-OV-3 and binding capability of T-CUS245C were assessed by Flow cytometry on a FACS Calibur (BD Biosciences) flow cytometer.",
            "startOffset": 19435,
            "title": "Flow cytometry"
        },
        {
            "endOffset": 15718,
            "parents": [],
            "refoffsets": {
                "bib16": {
                    "endOffset": 15716,
                    "startOffset": 15714
                }
            },
            "secId": "sec1",
            "sentence": "Our previous study had successfully determined its DNA sequence and amino acid sequence, as well as the tertiary structure [16].",
            "startOffset": 15590,
            "title": "Introduction"
        },
        {
            "endOffset": 29319,
            "parents": [],
            "secId": "sec4",
            "sentence": "Trastuzumab is a humanized monoclonal antibody against HER2/neu protein approved by FDA for treating breast and gastric cancer.",
            "startOffset": 29192,
            "title": "Discussion"
        },
        {
            "endOffset": 21969,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.8",
            "sentence": "Experimental data were presented as mean \u00b1 SD and analyzed by SPSS 19.0.",
            "startOffset": 21897,
            "title": "Mathematical and statistical analysis"
        },
        {
            "endOffset": 19187,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "After centrifuge and dialysis, Float-A-Lyzer G2 with the MWCO of 100 kDa (Spectrum Laboratories, Inc) was utilized to get rid of the CUS245C, while T-CUS 245C were collected and purified by 1.0 \u00d7 12 cm a Ni-NTA column (packed with 1.2 ml Ni+-NTA resin).",
            "startOffset": 18934,
            "title": "Conjugation of T-CUS 245C"
        },
        {
            "endOffset": 25917,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "These data were strongly related with IC50 of T-CUS245C showed in Table 1, indicates that the growth inhibition potency of ITs may not consistent with the level of the antigen expression.",
            "startOffset": 25730,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 22005,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.8",
            "sentence": "Two groups were analyzed by t-test.",
            "startOffset": 21970,
            "title": "Mathematical and statistical analysis"
        },
        {
            "endOffset": 14769,
            "parents": [],
            "secId": "sec1",
            "sentence": "Trastuzumab is a humanized monoclonal antibody against HER2/neu protein.",
            "startOffset": 14697,
            "title": "Introduction"
        },
        {
            "endOffset": 18869,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "The mixtures were allowed be reacted with four-fold of DTT-reduced CUS245C at 23 \u00b0C for 18 h.",
            "startOffset": 18776,
            "title": "Conjugation of T-CUS 245C"
        },
        {
            "endOffset": 23478,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Generally, the proliferation inhibition of T-CUS245C on HER2 positive cells is dose-dependent and is remarkably more significant than that of trastuzumab, CUS245C, and T + CUS245C when their concentrations were less than 102nM.",
            "startOffset": 23251,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 25729,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "MCF-7 and MDA-MB-231 were considered as HER2 negative cells.",
            "startOffset": 25669,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 19954,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "For verifying T-CUS245C binding ability, trastuzumab and T-CUS245C were used respectively on SK-OV-3 and detected by anti-human-APC as a secondary antibody.",
            "startOffset": 19798,
            "title": "Flow cytometry"
        },
        {
            "endOffset": 22709,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "The molecular weight and purity of T-CUS245C were analyzed by SDS-PAGE and Western blotting.",
            "startOffset": 22617,
            "title": "T-CUS245C construction"
        },
        {
            "endOffset": 32307,
            "parents": [],
            "secId": "sec4",
            "sentence": "Hence, understanding the mechanisms by which cells interact with environment and the role internalization plays in may be of great help to pick up targets suitable for IT treatment.",
            "startOffset": 32126,
            "title": "Discussion"
        },
        {
            "endOffset": 17590,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                },
                {
                    "id": "sec2.1",
                    "title": "Cell lines and reagents"
                }
            ],
            "secId": "sec2.1.2",
            "sentence": "Goat anti-mouse IgG-HRP (Santa Cruz Biotechnology).",
            "startOffset": 17539,
            "title": "Reagents"
        },
        {
            "endOffset": 20797,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.7",
            "sentence": "CUS245C and T-CUS245C we applied were visualized by anti-CUS245C labeled with FITC using Fluorescein FITC Protein Labeling Kit (FITC, Thermo Fisher Scientific).",
            "startOffset": 20637,
            "title": "Confocal microscopy"
        },
        {
            "endOffset": 14200,
            "parents": [],
            "refoffsets": {
                "bib5": {
                    "endOffset": 14198,
                    "startOffset": 14195
                },
                "bib6": {
                    "endOffset": 14198,
                    "startOffset": 14195
                },
                "bib7": {
                    "endOffset": 14198,
                    "startOffset": 14195
                }
            },
            "secId": "sec1",
            "sentence": "Besides, the heterogenicity of ITs as a foreign substance is likely to cause systemic auto-immune diseases, like severe dermatitis and has a potential to generate neutral antibodies result in cancer relapse [5\u20137].",
            "startOffset": 13987,
            "title": "Introduction"
        },
        {
            "endOffset": 17712,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "We inserted a cysteine residue to the 245th nucleotide sequence of CUS and labeled it with a His-tag.",
            "startOffset": 17611,
            "title": "CUS245C expression"
        },
        {
            "endOffset": 13694,
            "parents": [],
            "secId": "sec1",
            "sentence": "However, very few of them have reached to the clinic.",
            "startOffset": 13641,
            "title": "Introduction"
        },
        {
            "endOffset": 13820,
            "parents": [],
            "refoffsets": {
                "bib2": {
                    "endOffset": 13818,
                    "startOffset": 13817
                }
            },
            "secId": "sec1",
            "sentence": "The main issue impeding the clinical utility of immunotoxins is the off-target side-effects caused by an unstable linker [2].",
            "startOffset": 13695,
            "title": "Introduction"
        },
        {
            "endOffset": 23916,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "For 3-day experiments, the IC50 of T-CUS245C towards BT-474 and SK-BR-3 are above 0.1 nM but decreased to 0.07 \u00b1 1.23 nM when it comes to SK-OV-3 (Table 1).",
            "startOffset": 23760,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 29665,
            "parents": [],
            "refoffsets": {
                "bib17": {
                    "endOffset": 29660,
                    "startOffset": 29658
                },
                "bib19": {
                    "endOffset": 29663,
                    "startOffset": 29661
                }
            },
            "secId": "sec4",
            "sentence": "Our previous studies have shown a potent cytotoxicity of a type 1 RIPs CUS245C and offered the evidences that it could be a perfect candidate for forming an IT [17,19].",
            "startOffset": 29497,
            "title": "Discussion"
        },
        {
            "endOffset": 23591,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "However, as concentration further increased, the cytotoxicity of CUS245C emerged and rise dramatically (Fig. 2).",
            "startOffset": 23479,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 25061,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Interestingly, while the apoptosis of HER2 positive cells induced by trastuzumab and T + CUS245C are not so distinct as T-CUS245C did, they exerted anti-tumor efficacy on BT-474 when the concentrations beyond 0.1 nM (Fig. 2B), demonstrates that BT-474 is likely to be a trastuzumab-sensitive cell line even anti-tumor effectiveness of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) were absent.",
            "startOffset": 24607,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 31308,
            "parents": [],
            "secId": "sec4",
            "sentence": "Another interesting point is that apoptosis was barely induced in cells under trastuzumab stress, which means the trastuzumab-mediated effects were absent here, but it should not be underestimated in vivo since trastuzumab impart therapeutic benefit via ADCC and CDC when it is administered in vivo.",
            "startOffset": 31009,
            "title": "Discussion"
        },
        {
            "endOffset": 18403,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "The concentration and molecular masses of the CUS245C were determined by BCA Protein Assay Kit (Beyotime, China) and SDS-PAGE, respectively.",
            "startOffset": 18263,
            "title": "CUS245C expression"
        },
        {
            "endOffset": 29181,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.3",
            "sentence": "****p < 0.0001.",
            "startOffset": 29166,
            "title": "Internalization of T-CUS245C"
        },
        {
            "endOffset": 24607,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "This demonstrates a potent in vitro anti-tumor efficacy of T-CUS245C against HER2 positive cell lines, and among all cells been tested, SK-OV-3 might be the most sensitive one.",
            "startOffset": 24431,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 25668,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Mean florescent intensities (MFI) were acquired by flow cytometry and displayed on Fig. 2C. BT-474 has the highest HER2 expression level while SK-OV-3 and SK-BR-3 were relatively lower.",
            "startOffset": 25483,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 13498,
            "parents": [],
            "refoffsets": {
                "bib3": {
                    "endOffset": 13496,
                    "startOffset": 13495
                }
            },
            "secId": "sec1",
            "sentence": "Typically, the ITs are comprised of an antibody or an antibody fragment, a cytotoxic drug like a bacterial protein or a plant-derived ribosomal inactivating protein (RIP), and a suitable linker [3].",
            "startOffset": 13300,
            "title": "Introduction"
        },
        {
            "endOffset": 16205,
            "parents": [],
            "secId": "sec1",
            "sentence": "In this study, we conjugated trastuzumab to modified CUS245C (a recombinant CUS which a cysteine residue was inserted onto 245th amino acid sequence) by chemical linking and evaluated its anti-tumor activity in multiple cell lines with different HER2 expression level.",
            "startOffset": 15937,
            "title": "Introduction"
        },
        {
            "endOffset": 23759,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "This indicates that CUS245C has limited cytotoxic activity at low concentration, but when it was conjugated to trastuzumab, it possessed a potent cell killing ability.",
            "startOffset": 23592,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 19797,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.5",
            "sentence": "For HER2 expression, cells were incubated with FITC labeled trastuzumab (diluted to 1ng/105 cells) for 30 min at 4 \u00b0C and washed twice with PBS containing 1% FBS.",
            "startOffset": 19635,
            "title": "Flow cytometry"
        },
        {
            "endOffset": 22550,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "T-PDP were washed by 15 mM imidazole (Fig. A2 Lane 4\u201310).",
            "startOffset": 22493,
            "title": "T-CUS245C construction"
        },
        {
            "endOffset": 25180,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "To assess the cytotoxic specificity of T-CUS245C, HER2 negative cells MDA-MB-231 and MCF-7 were also applied.",
            "startOffset": 25071,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 17538,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                },
                {
                    "id": "sec2.1",
                    "title": "Cell lines and reagents"
                }
            ],
            "secId": "sec2.1.2",
            "sentence": "Mouse anti-human IgG1-APC, mouse anti-his-FITC were purchased from BD Bioscience (San Jose, CA).",
            "startOffset": 17442,
            "title": "Reagents"
        },
        {
            "endOffset": 31588,
            "parents": [],
            "secId": "sec4",
            "sentence": "Our confocal microscopy analysis showed that T-CUS245C can be taken up in to endocytic vesicles as well.",
            "startOffset": 31484,
            "title": "Discussion"
        },
        {
            "endOffset": 31923,
            "parents": [],
            "secId": "sec4",
            "sentence": "These results agree with what had been reported and ensure that our ITs exert their functions via a typical endocytosis pathway when ligands bind to their receptors.",
            "startOffset": 31758,
            "title": "Discussion"
        },
        {
            "endOffset": 15288,
            "parents": [],
            "refoffsets": {
                "bib1": {
                    "endOffset": 15286,
                    "startOffset": 15285
                }
            },
            "secId": "sec1",
            "sentence": "Although, the efficacy of trastuzumab is limited, it is a promising delivery candidate for ITs and it can exert its function by killing cells directly instead of signaling inhibition through being joined to a toxin [1].",
            "startOffset": 15069,
            "title": "Introduction"
        },
        {
            "endOffset": 32125,
            "parents": [],
            "secId": "sec4",
            "sentence": "Importantly, not all the receptors expressed on cellular surface have the potential to be internalized, some cell membrane proteins are more likely to adjust their expression at post-translation level.",
            "startOffset": 31924,
            "title": "Discussion"
        },
        {
            "endOffset": 14865,
            "parents": [],
            "refoffsets": {
                "bib10": {
                    "endOffset": 14863,
                    "startOffset": 14861
                },
                "bib9": {
                    "endOffset": 14860,
                    "startOffset": 14859
                }
            },
            "secId": "sec1",
            "sentence": "It has been approved by FDA in the therapy of treating breast cancer and gastric cancer [9,10].",
            "startOffset": 14770,
            "title": "Introduction"
        },
        {
            "endOffset": 22248,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.1",
            "sentence": "To determine whether combining trastuzumab with CUS would be practicable, we used an artificial disulfide bond to conjugate trastuzumab with recombinant CUS245C.",
            "startOffset": 22087,
            "title": "T-CUS245C construction"
        },
        {
            "endOffset": 17024,
            "parents": [],
            "secId": "sec1",
            "sentence": "This study provided a novel IT targeting HER2 using self-produced type I RIP CUS and remarkable improved antitumor effects of recombinant IT which represents a potentially attractive therapeutic modality for cancer treatment.",
            "startOffset": 16799,
            "title": "Introduction"
        },
        {
            "endOffset": 17441,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                },
                {
                    "id": "sec2.1",
                    "title": "Cell lines and reagents"
                }
            ],
            "secId": "sec2.1.2",
            "sentence": "Trastuzumab (Roche).",
            "startOffset": 17421,
            "title": "Reagents"
        },
        {
            "endOffset": 18933,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "The conjugating reaction was terminated by 0.1 M iodoacetamide.",
            "startOffset": 18870,
            "title": "Conjugation of T-CUS 245C"
        },
        {
            "endOffset": 19418,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.4",
            "sentence": "Purified protein was analyzed through 6% SDS-PAGE and 8% SDS-PAGE gel and Western blot analysis used mouse anti-CUS antibody as primary antibody and goat anti-mouse IgG-HRP as the secondary antibody.",
            "startOffset": 19219,
            "title": "SDS-PAGE and western blotting"
        },
        {
            "endOffset": 31483,
            "parents": [],
            "secId": "sec4",
            "sentence": "Many researches have studied the receptor-mediated endocytosis of ITs and found out that the internalization is through endocytosis and correlated with the cytolethal potency.",
            "startOffset": 31308,
            "title": "Discussion"
        },
        {
            "endOffset": 23160,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "To determine the cytotoxic effects of T-CUS245C, we exposed antigen-positive cell lines mentioned above to CUS245C, trastuzumab,T-CUS245C, and T + CUS245C for 3-day and 5-day treatments, respectively.",
            "startOffset": 22960,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 13986,
            "parents": [],
            "refoffsets": {
                "bib4": {
                    "endOffset": 13984,
                    "startOffset": 13983
                }
            },
            "secId": "sec1",
            "sentence": "When toxins are released from the delivery vehicles before getting to target cells, they tend to bind to normal tissues, leading to unexpected cellular necrosis [4].",
            "startOffset": 13821,
            "title": "Introduction"
        },
        {
            "endOffset": 25482,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "Subsequently, we test the extracellular level of HER2 on cells that we used.",
            "startOffset": 25406,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 29994,
            "parents": [],
            "secId": "sec4",
            "sentence": "Here, we implemented chemical conjugation methods to fuse trastuzumab to CUS245C, hoping that CUS245C can overcome the limitation of trastuzumab and wider it's therapeutic window.",
            "startOffset": 29815,
            "title": "Discussion"
        },
        {
            "endOffset": 16798,
            "parents": [],
            "secId": "sec1",
            "sentence": "Simultaneously, using confocal microscopy we verified that the lethal effect is mediated by antibody internalization and cytotoxin intracellular degradation.",
            "startOffset": 16641,
            "title": "Introduction"
        },
        {
            "endOffset": 17308,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                },
                {
                    "id": "sec2.1",
                    "title": "Cell lines and reagents"
                }
            ],
            "secId": "sec2.1.1",
            "sentence": "All cells were cultured in DMEM (Gibco, USA) supplemented with 10% FBS (Gibco, USA).",
            "startOffset": 17224,
            "title": "Cell line"
        },
        {
            "endOffset": 18578,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "10 mg Trastuzumab were dialyze against 20 mM PBS (pH7.5) and mixed with five-fold SPDP (20 mM in DMSO) and incubated at room temperature for 30min.",
            "startOffset": 18431,
            "title": "Conjugation of T-CUS 245C"
        },
        {
            "endOffset": 20924,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.7",
            "sentence": "Cells were seeded on glass coverslips in 6-well dishes at a density of 2 \u00d7 105 cells per well and allowed to attach overnight.",
            "startOffset": 20798,
            "title": "Confocal microscopy"
        },
        {
            "endOffset": 25406,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "The results in Fig. 2 and Table 1 showed that neither did MDA-MB-231 nor did MCF-7 react with trastuzumab, T + CUS245C or T-CUS245C (IC50 > 1000 ng/ml), confirming that the antigen binding is necessary for cytotoxic activity.",
            "startOffset": 25181,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        },
        {
            "endOffset": 14588,
            "parents": [],
            "secId": "sec1",
            "sentence": "HER2 is a member of ErbB family that has been considered as a critical regulator in cell proliferation and survival.",
            "startOffset": 14472,
            "title": "Introduction"
        },
        {
            "endOffset": 20129,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib17": {
                    "endOffset": 20127,
                    "startOffset": 20125
                }
            },
            "secId": "sec2.6",
            "sentence": "The dose- and time-dependent cytotoxic activity of drugs was measured by SRB assay as previously described [17].",
            "startOffset": 20017,
            "title": "Cytotoxic activity"
        },
        {
            "endOffset": 29814,
            "parents": [],
            "secId": "sec4",
            "sentence": "Utilizing CUS245C combining trastuzumab is likely a way of overcoming resistance issues via bypassing the signal pathway and killing cells directly.",
            "startOffset": 29666,
            "title": "Discussion"
        },
        {
            "endOffset": 17862,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.2",
            "sentence": "Escherichia coli BL21 (DE3) and expression vector pET32a (+) were applied for the expression of the CUS245C according to the manufacturer's protocol.",
            "startOffset": 17713,
            "title": "CUS245C expression"
        },
        {
            "endOffset": 20572,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.6",
            "sentence": "The cytotoxic activity was defined by IC50 values.",
            "startOffset": 20522,
            "title": "Cytotoxic activity"
        },
        {
            "endOffset": 30350,
            "parents": [],
            "secId": "sec4",
            "sentence": "In cytotoxicity study, the IC50 for SK-OV-3 is around 10pM, significantly lower than that of BT-474 and SK-BR-3.",
            "startOffset": 30238,
            "title": "Discussion"
        },
        {
            "endOffset": 31757,
            "parents": [],
            "secId": "sec4",
            "sentence": "Moreover, neither did CUS245C attach to cell nor did they be internalized into cytoplasm, illustrates that distinct internalization was enhanced mediated by antibodies.",
            "startOffset": 31589,
            "title": "Discussion"
        },
        {
            "endOffset": 18775,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "The excess SPDP and DTT were later removed by overnight dialysis.",
            "startOffset": 18710,
            "title": "Conjugation of T-CUS 245C"
        },
        {
            "endOffset": 14696,
            "parents": [],
            "refoffsets": {
                "bib8": {
                    "endOffset": 14694,
                    "startOffset": 14693
                }
            },
            "secId": "sec1",
            "sentence": "Its mutation or amplification is involved in enhanced aggressiveness of multiple kinds of malignancies [8].",
            "startOffset": 14589,
            "title": "Introduction"
        },
        {
            "endOffset": 22054,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.8",
            "sentence": "P < 0.05 was considered significantly different.",
            "startOffset": 22006,
            "title": "Mathematical and statistical analysis"
        },
        {
            "endOffset": 29496,
            "parents": [],
            "secId": "sec4",
            "sentence": "Type 1 RIPs are commonly used toxic payload of ITs.",
            "startOffset": 29445,
            "title": "Discussion"
        },
        {
            "endOffset": 13299,
            "parents": [],
            "refoffsets": {
                "bib1": {
                    "endOffset": 13295,
                    "startOffset": 13294
                },
                "bib2": {
                    "endOffset": 13297,
                    "startOffset": 13296
                }
            },
            "secId": "sec1",
            "sentence": "Immunotoxins (ITs) are antibody-cytotoxin compositions that have been under development for the treatment of cancers for several decades, and hundreds of studies have exhibited the potential application of ITs in pre-clinical studies and in clinical trials [1,2].",
            "startOffset": 13036,
            "title": "Introduction"
        },
        {
            "endOffset": 15937,
            "parents": [],
            "secId": "sec1",
            "sentence": "We also found out that CUS is capable of inhibiting the proliferation of various tumor cells significantly in vitro with cytotoxicity 4 to 7 times stronger than that of other RIPs, such as luffaculin and trichosanthin.",
            "startOffset": 15719,
            "title": "Introduction"
        },
        {
            "endOffset": 13640,
            "parents": [],
            "secId": "sec1",
            "sentence": "With the targeting characteristics of antibodies and cytotoxicity of payloads, immunotoxins are supposed to be effective in treating cancers.",
            "startOffset": 13499,
            "title": "Introduction"
        },
        {
            "endOffset": 18709,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.3",
            "sentence": "CUS245C dimers were reduced into monomers by 0.5 M Dithiothreitol (DTT, Beyotime) for 30min to expose sulfydryl groups thoroughly.",
            "startOffset": 18579,
            "title": "Conjugation of T-CUS 245C"
        },
        {
            "endOffset": 29166,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.3",
            "sentence": "Date shown are mean value of inhibition rate of drugs for SK-OV-3, **p < 0.05, ***p < 0.001.",
            "startOffset": 29074,
            "title": "Internalization of T-CUS245C"
        },
        {
            "endOffset": 29445,
            "parents": [],
            "secId": "sec4",
            "sentence": "However, majority of patients might become resistant during treatments and helping them retain sensitivity can be beneficial.",
            "startOffset": 29320,
            "title": "Discussion"
        },
        {
            "endOffset": 30601,
            "parents": [],
            "secId": "sec4",
            "sentence": "Whereas, HER2 expression on SK-OV-3 is similar with that of SK-BR-3 but less than that of BT-474, demonstrating that the cytotoxicity of IT is not severely correlated with antigen expression level and SK-OV-3 cells are most reactive one to T-CUS245C.",
            "startOffset": 30351,
            "title": "Discussion"
        },
        {
            "endOffset": 21184,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.7",
            "sentence": "After washed three times with PBS, cells were fixed and permeabilized and CUS245C were detected by anti- CUS245C-FITC.",
            "startOffset": 21066,
            "title": "Confocal microscopy"
        },
        {
            "endOffset": 15424,
            "parents": [],
            "refoffsets": {
                "bib12": {
                    "endOffset": 15422,
                    "startOffset": 15420
                }
            },
            "secId": "sec1",
            "sentence": "Cucurmosin (CUS) is a typical type I RIP plant-derived cytotoxin without unspecific cellular adherence caused by lectin properties [12].",
            "startOffset": 15288,
            "title": "Introduction"
        },
        {
            "endOffset": 21323,
            "parents": [
                {
                    "id": "sec2",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec2.7",
            "sentence": "Lysosomes were further stained with specific dyes for lysosomes (Lyso-Tracker Red, Molecular probes), and nucleus were stained by Hoechst.",
            "startOffset": 21185,
            "title": "Confocal microscopy"
        },
        {
            "endOffset": 15068,
            "parents": [],
            "refoffsets": {
                "bib11": {
                    "endOffset": 15066,
                    "startOffset": 15064
                }
            },
            "secId": "sec1",
            "sentence": "Unfortunately, only a quarter of patients have the possibility to benefit from anti- HER2 treatments, and a large part of them become resistant to this target therapy within a short period of time [11].",
            "startOffset": 14866,
            "title": "Introduction"
        },
        {
            "endOffset": 24123,
            "parents": [
                {
                    "id": "sec3",
                    "title": "Results"
                }
            ],
            "secId": "sec3.2",
            "sentence": "The same cytotoxicity tendency can be observed in 5-day treatments, except the IC50 values decrease 10-fold to extremely low concentrations (Fig. 2B), illustrates a time-dependent cytotoxicity of T-CUS245C.",
            "startOffset": 23917,
            "title": "Cytotoxicity of T-CUS245C on different cell lines"
        }
    ],
    "docId": "S0006291X19304796",
    "metadata": {
        "asjc": [
            "1303",
            "1304",
            "1307",
            "1312"
        ],
        "authors": [
            {
                "email": null,
                "first": "Jiani",
                "initial": "J.",
                "last": "Xiong"
            },
            {
                "email": null,
                "first": "Caiyun",
                "initial": "C.",
                "last": "Zhang"
            },
            {
                "email": null,
                "first": "Shuifa",
                "initial": "S.",
                "last": "Wu"
            },
            {
                "email": null,
                "first": "Xiaofan",
                "initial": "X.",
                "last": "Gu"
            },
            {
                "email": null,
                "first": "Yumei",
                "initial": "Y.",
                "last": "Cai"
            },
            {
                "email": null,
                "first": "Chunseng",
                "initial": "C.",
                "last": "Xu"
            },
            {
                "email": null,
                "first": "Zhou",
                "initial": "Z.",
                "last": "Chen"
            },
            {
                "email": null,
                "first": "Jiancheng",
                "initial": "J.",
                "last": "Sun"
            },
            {
                "email": null,
                "first": "Xiangxin",
                "initial": "X.",
                "last": "Wu"
            },
            {
                "email": null,
                "first": "Xiuhua",
                "initial": "X.",
                "last": "You"
            },
            {
                "email": null,
                "first": "Zhihong",
                "initial": "Z.",
                "last": "Huang"
            },
            {
                "email": "jmxie@fjmu.edu.cn",
                "first": "Jieming",
                "initial": "J.",
                "last": "Xie"
            }
        ],
        "doi": "10.1016/j.bbrc.2019.03.090",
        "firstpage": "15",
        "issn": "0006291X",
        "keywords": [
            " CUS 245C",
            " T-CUS 245C",
            "Immunotoxins",
            "Internalization",
            "Trastuzumab"
        ],
        "lastpage": "21",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC"
        ],
        "title": "Recombinant cucurmosin-based immunotoxin targeting HER-2 with potent in vitro anti-cancer cytotoxicity"
    }
}